Left Menu
Development News Edition

Pfizer not yet ready to release COVID-19 vaccine data

The data monitoring board is scheduled to make its first assessment of the vaccine's performance after 32 participants in the trial become infected with the novel coronavirus. As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech.

Reuters | Updated: 27-10-2020 17:28 IST | Created: 27-10-2020 17:16 IST
Pfizer not yet ready to release COVID-19 vaccine data
Representative Image Image Credit: Pixabay

Drugmaker Pfizer Inc said on Tuesday it was not yet ready to release data from the late-stage trial of the COVID-19 vaccine candidate it is developing with Germany's BioNTech SE. Pfizer's CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month, but the company said in a presentation that the independent data monitoring board which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet.

Shares were flat at $37.93 before the opening bell. U.S. President Donald Trump had said a vaccine could be available before the Nov. 3 election, but in recent weeks his administration has emphasized that one will be ready this year.

Pfizer hopes to be the first U.S. drugmaker to unveil successful data from a late-stage COVID-19 vaccine trial, ahead of rival Moderna Inc. Pfizer and BioNTech launched their 44,000 volunteer phase 3 study of their vaccine candidate in late July. The data monitoring board is scheduled to make its first assessment of the vaccine's performance after 32 participants in the trial become infected with the novel coronavirus.

As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech. Pfizer reported quarterly earnings that beat estimates by one cent, helped by better-than-expected sales of its cancer drug Ibrance.

Overall sales fell 4.3% in the third quarter, hurt by a plunge in sales of its off-patent pain drug Lyrica and a $500 million hit to sales from the COVID-19 pandemic. Sales of cancer drug Ibrance grew 6% to $1.36 billion, beating analyst estimates of $1.39 billion, despite increased competition from Eli Lilly's Verzenio.

Excluding items, Pfizer earned 72 cents per share, beating analysts estimates of 71 cents per share, according to IBES data from Refinitiv.


TRENDING

OPINION / BLOG / INTERVIEW

Turbulence surrounding tobacco control in Ghana

... ...

Smart healthcare: IoT redefining the way healthcare is delivered

As the world is embracing the new wave of digitalization triggered by the pandemic and the arrival of 5G, the adoption of IoT devices will further boom. With adoption set to soar, IoT security issues and other challenges cant be ignored any...

Refugee compassion and response: Ideas to mitigate disasters now and in their future

Their homeland becomes a forbidden territory for them and more likely than not, their journey to foreign soil is no less traumatizing, not to say deadly. It is crucial to help refugees live a life of dignity and purpose....

Inadequate water infrastructure causes a tidal wave of coronavirus in rural Alaska

... ...

Videos

Latest News

GM flips to California's side in pollution fight with Trump

General Motors says it will no longer support the Trump administration in legal efforts to end Californias right to set its own clean-air standards. CEO Mary Barra said in an letter Monday to environmental groups that GM will pull out of th...

Bengal reports 47 more COVID deaths, 3,557 new cases

The COVID-19 death toll in West Bengal rose to 8,072 after 47 more people succumbed to the disease on Monday, while 3,557 new cases of infection took the tally to 4,59,918, the state health department said in a bulletin. The caseload of Kol...

EU invites Biden to patch up trans-Atlantic ties

European Union chief Charles Michel is inviting Joe Biden once he is US president to come visit and patch up trans-Atlantic relations that have suffered over the past four years under President Donald Trump. Now is the time to join forces. ...

Fire at petroleum products station in Jeddah extinguished -SPA citing Saudi official

An official at Saudi Arabias ministry of energy said that a fire broke out in a fuel tank at a petroleum products distribution station in north Jeddah as a result of an attack with a projectile, Saudi state news agency SPA reported on Monda...

Give Feedback